Amitiza is a prostone and is a locally acting chloride channel activator, indicated in the US to treat chronic idiopathic constipation (CIC) in adults and opioid-induced constipation (OIC) in adults with chronic, non-cancer pain.
The amendment of the collaboration agreement will see several modifications carried out such as the extension of the current term, minimum commercial investment during the current term and various governance changes allowing Takeda additional flexibility in commercializing Amitiza.
The extended term will begin on 1 January 2021, under which Takeda will split with Sucampo the gross profits of branded Amitiza for any dosage strength and form for the existing indications in the US and Canada.
Additionally, on 1 April 2015 Takeda will no longer reimburse Sucampo for the product details made by Sucampo sales representatives to healthcare professionals as well as other ancillary costs of the sales force.
Sucampo chief executive officer Peter Greenleaf said the extended collaboration allows the company to share in the long-term value of Amitiza.
"Takeda and Sucampo are aligned in our objectives for the brand, and I believe this newly extended collaboration and license agreement positions the companies more strongly than ever to help grow the Amitiza business," Greenleaf said.